112 related articles for article (PubMed ID: 33560216)
41. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
[TBL] [Abstract][Full Text] [Related]
42. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
43. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
45. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
46. Noninvasive Assessment of
Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
[TBL] [Abstract][Full Text] [Related]
47. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
Kuwahara K; Ohba S; Nakae S; Hattori N; Pareira ES; Yamada S; Sasaki H; Abe M; Hasegawa M; Hirose Y
Brain Tumor Pathol; 2019 Oct; 36(4):135-143. PubMed ID: 31324999
[TBL] [Abstract][Full Text] [Related]
48. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
49. Dynamic FET PET Imaging of a "Butterfly" IDH-Wildtype Anaplastic Astrocytoma.
Galldiks N; Brunn A; Fink GR; Langen KJ
Clin Nucl Med; 2019 Oct; 44(10):e581-e582. PubMed ID: 31348085
[TBL] [Abstract][Full Text] [Related]
50. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract][Full Text] [Related]
51. IDH1 R132H mutation in a pilocytic astrocytoma: a case report.
Behling F; Steinhilber J; Tatagiba M; Bisdas S; Schittenhelm J
Int J Clin Exp Pathol; 2015; 8(9):11809-13. PubMed ID: 26617931
[TBL] [Abstract][Full Text] [Related]
52. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
[No Abstract] [Full Text] [Related]
53. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
54. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
55. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
56. The Prognostic Significance of RB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas.
Richardson TE; Walker JM
J Neuropathol Exp Neurol; 2020 Sep; 79(9):1019-1023. PubMed ID: 32791525
[No Abstract] [Full Text] [Related]
57. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
58. High-level Sp1 is Associated with Proliferation, Invasion, and Poor Prognosis in Astrocytoma.
Chen YT; Tsai HP; Wu CC; Chen CY; Chai CY; Kwan AL
Pathol Oncol Res; 2019 Jul; 25(3):1003-1013. PubMed ID: 29948615
[TBL] [Abstract][Full Text] [Related]
59. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
[TBL] [Abstract][Full Text] [Related]
60. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
